Dimerix Receives Initial $10 Million Upfront Payment Under Everest Medicines License Deal; Shares Gain 4%
MT Newswires Live11:53
Dimerix (ASX:DXB) received an initial $10 million upfront payment under a license agreement with Everest Medicines, according to a Thursday filing with the Australian bourse.
Everest holds exclusive rights to commercialize DMX-200 for the treatment of kidney disease focal segmental glomerulosclerosis across Greater China, South Korea, and Southeast Asia.
Dimerix said it is eligible to receive up to an additional $330 million in success-based development, regulatory, and commercial milestone payments, in addition to tiered royalties on net sales of the DMX-200 in the licensed regions.
The company's shares gained 4% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
